N.P. Koper

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol

Paul Devroey, R. Boostanfar, N.P. Koper et al. · Human Reproduction · 2009 · 213 citations · Full text

Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis

Lambertus A. Kiemeney, J. Alfred Witjes, R.P. Heijbroek et al. · British Journal of Urology · 1994 · 104 citations

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

C. Saura Manich, Joyce O’Shaughnessy, Philippe Aftimos et al. · Annals of Oncology · 2021 · 103 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis

Jeffrey A. Cohen, Anna N. Belova, Krzysztof Selmaj et al. · JAMA Neurology · 2015 · 73 citations